...
首页> 外文期刊>Cancer biology & therapy >Enhanced immune response to gastric cancer specific antigen Peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion.
【24h】

Enhanced immune response to gastric cancer specific antigen Peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion.

机译:通过与CpG寡脱氧核苷酸共包裹在纳米乳剂中,增强了对胃癌特异性抗原肽的免疫反应。

获取原文
获取原文并翻译 | 示例
           

摘要

CpG oligodeoxynucleotides (CpG ODN) have been shown to have potent adjuvant activity for a wide range of antigens. Of particular interest is their improved activity when closely associated with the antigen. The purpose of this study is to construct a nanovaccine coencapsulated with a gastric cancer specific antigen MG7 mimotope peptide and adjuvant CpG ODN 1645 using new nanotechnology as nanoemulsion and evaluate its immunocompetence. Nanoemulsion vaccine was prepared using magnetic ultrasound methods. BALB/c mice were immunized and the in vivo effectiveness was evaluated using tumor challenge assay. It was shown that the tumor masses formed in the mice immunized with coencapsulated nanovaccine (0.0825 g) markedly smaller (P < 0.01) than those formed in the mice immunized with nanovaccine encapsulated with antigen peptide alone (0.4465 g). A tumor inhibiting rate as high as 82.5% of the coencapsulated nanovaccine was obtained, while nanovaccine encapsulated with peptide only could not achieve the sameeffect (28.5%) (P < 0.01). Enzyme-linked immunospot assay (ELISPOT) showed that immunization using MG7 mimotope peptide coencapsulated with CpG ODN within the same nanoemulsion enhanced the frequency of splenocytes secreting IFN-gamma significantly (P < 0.01) when compared with immunization using MG7 peptide encapsulated in nanoemulsion alone (197spots/1 x 10(6) vs. 73 spots/1 x 10(6)). Cellular ELISA indicated that serum titer of antibody against MG7-Ag was significantly higher (P < 0.01) in mice immunized with coencapsulation form nanovaccine (0.7884) than that in the group immunized with nanovaccine encapsulated with MG7 peptide alone (0.3616). Using intracellular flow cytometric analysis, it was found that the IFN-gamma response was contributed by CD4+ T-cells. Our experiments suggest that a vaccinal approach using nano-delivery system carrying in tumoral epitope and CpG ODN as adjuvant may have important implications for cancer therapy.
机译:CpG寡脱氧核苷酸(CpG ODN)已显示对多种抗原具有有效的佐剂活性。特别感兴趣的是当它们与抗原紧密结合时它们的活性提高。这项研究的目的是使用新的纳米技术作为纳米乳液,构建与胃癌特异性抗原MG7模拟表位肽和佐剂CpG ODN 1645共封装的纳米疫苗,并评估其免疫能力。使用电磁超声方法制备了纳米乳疫苗。免疫BALB / c小鼠,并使用肿瘤激发试验评估体内效力。结果表明,用共包封的纳米疫苗(0.0825 g)免疫的小鼠中形成的肿瘤块(P <0.01)比用单独包被抗原肽的纳米疫苗免疫的小鼠中的肿瘤块(0.4465 g)明显小(P <0.01)。共包封的纳米疫苗的抑瘤率高达82.5%,而仅用肽包封的纳米疫苗达不到相同的效果(28.5%)(P <0.01)。酶联免疫斑点法(ELISPOT)显示,与使用单独封装在纳米乳液中的MG7肽进行免疫相比,在同一纳米乳液中使用与CpG ODN共封装的MG7拟表位肽进行的免疫显着提高了脾细胞分泌IFN-γ的频率(P <0.01)。 197点/ 1 x 10(6)与73点/ 1x 10(6))。细胞酶联免疫吸附试验(ELISA)表明,用纳米囊疫苗共包被免疫的小鼠(0.7884)的抗MG7-Ag抗体的血清滴度明显高于仅用MG7肽包囊的纳米疫苗免疫的小鼠的血清滴度(0.3616)。使用细胞内流式细胞术分析,发现IFN-γ应答是由CD4 + T细胞促成的。我们的实验表明,使用携带肿瘤抗原决定簇和CpG ODN作为佐剂的纳米传递系统的疫苗接种方法可能对癌症治疗具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号